Скачать или смотреть Dr. Payal Kohli: Rethinking LDL Strategy

In this expert commentary, Payal Kohli, MD breaks down the latest findings from LDL-lowering trials like FOURIER and ODYSSEY, emphasizing that “lower is better, faster, and for longer.” She explains how earlier and sustained LDL reduction leads to greater cardiovascular risk reduction, even when patients eventually reach the same cholesterol levels. Dr. Kohli addresses challenges such as statin-related nocebo effects, medication resistance, and the underuse of combination therapy in high-risk ASCVD patients. Furthermore, Dr. Kohli explores future directions in lipid management, including inclisiran, CRISPR-based gene editing, and shifting global guidelines, pointing toward a more aggressive and patient-centered approach to prevention.